Eli Lilly and Company (LLY)vsNutex Health Inc (NUTX)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
NUTX
Nutex Health Inc
$119.20
+6.41%
HEALTHCARE · Cap: $772.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 7347% more annual revenue ($65.18B vs $875.26M). LLY leads profitability with a 31.7% profit margin vs 8.1%. NUTX trades at a lower P/E of 10.6x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
NUTX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+71.6%
Fair Value
$362.71
Current Price
$119.20
$243.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Attractively priced relative to earnings
Every $100 of equity generates 59 in profit
Strong operational efficiency at 97.5%
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Smaller company, higher risk/reward
Revenue declined 41.1%
Earnings declined 86.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Return on Equity, Operating Margin.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : NUTX
The primary concerns for NUTX are Market Cap, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while NUTX is a value play — different risk/reward profiles.
NUTX carries more volatility with a beta of 2.02 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 52/100), backed by strong 31.7% margins and 42.6% revenue growth. NUTX offers better value entry with a 71.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?